Home › Research › Digital health tools
Representation of patients with dementia in clinical trials of donepezil
Gill SS, Bronskill SE, Mamdani M, Sykora K, Li P, Shulman KI, Anderson GM, Hillmer MP et al.. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2004-12-15
Topic: Drug trials: efficacy and safety
Plain-language summary
Objectives To evaluate the representation of frail older adults in randomized controlled trials (RCTs), and to assess consequences of under representation by analyzing drug discontinuation rates. Methods A cohort of older adults newly dispensed donepezil in Ontario between September 2001 and March 2002 was constructed using administrative data. A systematic review of the literature identified RCTs of donepezil. Patients dispensed donepezil were then compared to clinical trial subjects. Discontinuation rates were examined for patients with and without potential contraindications to this drug. Results There were 6,424 older adults in the Ontario cohort with new claims for donepezil. Ten RCTs evaluating the use of donepezil were identified (n = 3,423). Between 51% and 78% of the Ontario cohort would have been ineligible for RCT enrollment. Patients dispensed donepezil were older (80.3 vs. 73.7 years, p < 0.001) and more likely to be in long-term care (14.1 vs. 7.1%, p < 0.001) than RCT subjects. Overall, 27.8% of the Ontario cohort discontinued donepezil within seven months of initial prescription. Discontinuation rates were significantly higher for patients with a history of obstructive lung disease, active cardiovascular disease, or Parkinsonism. Conclusions Fewer than half of the older adults dispensed donepezil in Ontario would have been eligible to participate in the RCTs that established the efficacy of this drug. Discontinuation rates were higher among patient groups not represented in the trials. Clinicians should carefully assess the potential risks and benefits of such drug therapies for older patients with dementia.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gill, S. S., Bronskill, S. E., Mamdani, M., Sykora, K., Li, P., Shulman, K. I., et al. (2004). Representation of patients with dementia in clinical trials of donepezil. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.
Vancouver
Gill SS, Bronskill SE, Mamdani M, Sykora K, Li P, Shulman KI, et al. Representation of patients with dementia in clinical trials of donepezil. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique. 2004. PMID: 15604527.
BibTeX
@article{gill2004-15604527,
author = {Gill, S. S. and Bronskill, S. E. and Mamdani, M. and Sykora, K. and Li, P. and Shulman, K. I. and Anderson, G. M. and Hillmer, M. P. and others},
title = {{Representation of patients with dementia in clinical trials of donepezil}},
journal = {The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique},
year = {2004},
pmid = {15604527}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Patients dispensed donepezil were then compared to clinical trial subjects.
- Results There were 6,424 older adults in the Ontario cohort with new claims for donepezil.
- Overall, 27.8% of the Ontario cohort discontinued donepezil within seven months of initial prescription.
- Discontinuation rates were significantly higher for patients with a history of obstructive lung disease, active cardiovascular disease, or Parkinsonism.
New to this subject? Start with our plain-English guide: Digital health →
Study details
- Study designsystematic review
- Participants3,423
- Effect size7.1%; 27.8%
- Evidence strengthHigh
How this study scored 78/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 45 of the 58 points we could judge it on, which is 78 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2004 — older than 20 years, still counted |
| Sample size | 3 / 4 | 3,423 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 15604527) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 45 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 45 of the 58 points we could judge it on is 78 out of 100. |
| Total | 78 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Digital health tools from nearby years
Also tagged “cholinesterase”
272 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 272 tagged studies.